Tuesday, June 25, 2024
Home Tags BridgeBio

Tag: BridgeBio

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Stud…...

0
- NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At...

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA...

0
Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

0
PALO ALTO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic...

BridgeBio Pharma and the University of California, San Diego Announce Collaboration...

0
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego...

BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the...

0
– Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over...

BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™...

0
Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and...

Press Realease

Business News

Cricket

Weather News

Lifestyle

World News

UK / USA News

Local News